

**ALKEM LABORATORIES LTD.**

**Regd. Office :** ALKEM HOUSE, Senapati Bapat Marg,  
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: [contact@alkem.com](mailto:contact@alkem.com) • Website: [www.alkemlabs.com](http://www.alkemlabs.com)
- CIN: L00305MH1973PLC174201

04<sup>th</sup> August, 2021

<b>The Corporate Relationship Department BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001.  <i>Scrip Code: 539523</i>	<b>National Stock Exchange of India Limited</b> Exchange Plaza, Bandra Kurla Complex, Bandra East , Mumbai 400 051.  <i>Scrip Symbol: ALKEM</i>
---	---

Dear Sirs,

**Sub: Press Release – ALKEM launches Ibuprofen and Famotidine Tablets in the  
United States.**

This is to intimate you that Alkem Laboratories Limited (the “Company”) has launched Ibuprofen and Famotidine Tablets in the United States, following an approval from the United States Food and Drug Administration (US FDA). A press release in this regard is enclosed herewith.

Kindly take the same on record.

Sincerely,  
For **Alkem Laboratories Limited**

**Basudeo N. Singh**  
**Executive Chairman**  
**DIN: 00760310**

**Encl: a/a**

**ALKEM LABORATORIES LTD.**

**Regd. Office :** ALKEM HOUSE, Senapati Bapat Marg,  
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: [contact@alkem.com](mailto:contact@alkem.com) • Website: [www.alkemlabs.com](http://www.alkemlabs.com)
- CIN: L00305MH1973PLC174201

**Alkem Launches Ibuprofen and Famotidine Tablets in the United States**

**Mumbai, August 4, 2021:** Alkem Laboratories Ltd. (Alkem) today announced the launch of Ibuprofen and Famotidine Tablets (800 mg/26.6 mg) in the United States, following an approval from the United States Food and Drug Administration (US FDA). Ibuprofen and Famotidine Tablets is AB-rated generic therapeutic equivalent version of Horizon Medicines LLC's Duexis® Tablets, 800 mg/26.6 mg.

This is the first generic approval of Duexis® Tablets, 800 mg/26.6 mg by the US FDA. The launch is a subject of ongoing litigation.

**About Alkem Laboratories Ltd.**

Established in 1973 and headquartered in Mumbai, Alkem (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and International markets. With a portfolio of more than 800 brands in India, Alkem is ranked the fifth largest pharmaceutical company in India in terms of domestic sales (Source: IQVIA March 2021). The Company also has presence in more than 40 international markets, with the United States being its key focus market.

For more information on Alkem, please visit [www.alkemlabs.com](http://www.alkemlabs.com)

**For further information or queries, please contact:**

**Gagan Borana**

Investor Relations

E-mail: [gagan.borana@alkem.com](mailto:gagan.borana@alkem.com)